Skip to main content
main-content
Top

11-01-2019 | Rheumatology | News | Article

News in brief

Predictors of outcomes identified in JIA-associated uveitis

medwireNews: Demographic factors, measures of disease activity, and the type of treatment used are associated with 2-year outcomes among patients with juvenile idiopathic arthritis (JIA)-associated uveitis, according to findings from the ICON-JIA study.

Arnd Heiligenhaus (University of Duisburg-Essen, Münster, Germany) and colleagues analyzed data from 954 JIA patients, 11.1% of whom developed uveitis over 2 years. Of these 106 patients, 80.0% had achieved uveitis inactivity with anti-inflammatory treatment at the 2-year follow-up after uveitis onset.

As reported in Rheumatology, patients who had inactive uveitis for at least 6 months during this period were significantly older at JIA and uveitis onset, more likely to be receiving adalimumab treatment, and had lower rates of topical corticosteroid use compared with those who did not achieve inactive disease. On the other hand, patients with subsequent uveitis reactivation were younger at uveitis onset and more likely to have active JIA (cJADAS<4.5) than patients who maintained inactive disease.

The study authors also report a number of factors associated with the development of uveitis-related complications; patients who developed complications were older at JIA onset and had a shorter interval between JIA and uveitis diagnosis and worse visual acuity than those who did not.

Therefore, “demographic risk factors, JIA disease and uveitis activity scores and adalimumab are significant predictors for the 2-year outcome of JIA-associated uveitis patients,” conclude the researchers.

By Claire Barnard

medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group

See also: